A Review of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer

Neoadjuvant chemoradiotherapy has become the standard treatment for locally advanced rectal cancer. Neoadjuvant chemoradiotherapy not only can reduce tumor size and recurrence, but also increase the tumor resection rate and anus retention rate with very slight side effect. Comparing with preoperative chemotherapy, preoperative chemoradiotherapy can further reduce the local recurrence rate and downstage. Middle and low rectal cancers can benefit more from neoadjuvant chemradiotherapy than high rectal cancer. It needs to refine the selection of appropriate patients and irradiation modes for neoadjuvant chemoradiotherapy. Different therapeutic reactions to neoadjuvant chemoradiotherapy affect the type of surgical techniques, hence calling for the need of much attention. Furthermore, many problems such as accurate staging before surgery, selection of suitable neoadjuvant chemoradiotherapy method, and sensitivity prediction to preoperative radiotherapy need to be well settled.

[1]  C. McConkey,et al.  Pathological complete response following pre-operative chemoradiotherapy in rectal cancer: analysis of phase II/III trials. , 2005, The British journal of radiology.

[2]  B. Uzzan,et al.  Microsatellite instability does not predict the efficacy of chemotherapy in metastatic colorectal cancer. A systematic review and meta-analysis. , 2009, Anticancer research.

[3]  Vincenzo Canzonieri,et al.  Long-Term Outcome of Patients with Complete Pathologic Response after Neoadjuvant Chemoradiation for cT3 Rectal Cancer: Implications for Local Excision Surgical Strategies , 2011, Annals of Surgical Oncology.

[4]  Daniel J Sargent,et al.  Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. , 2003, The New England journal of medicine.

[5]  J. Gama-Rodrigues,et al.  Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control. , 2014, International journal of radiation oncology, biology, physics.

[6]  V. Georgoulias,et al.  Multicenter dose-finding study of concurrent capecitabine and radiotherapy as adjuvant treatment for operable rectal cancer. , 2003, International journal of radiation oncology, biology, physics.

[7]  Sang‐wook Lee,et al.  Preoperative concurrent radiotherapy with capecitabine before total mesorectal excision in locally advanced rectal cancer. , 2005, International journal of radiation oncology, biology, physics.

[8]  A. Hinke,et al.  Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Kładny,et al.  Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[10]  G. Beretta,et al.  Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  L. Gunderson,et al.  Sphincter‐preserving radiation therapy for rectal cancer: a simulation study using three‐dimensional computerized technology , 2006, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[12]  R. Fraser,et al.  Acute effects of therapeutic irradiation for prostatic carcinoma on anorectal function , 1998, Gut.

[13]  K. Song,et al.  Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer. , 2002, International journal of radiation oncology, biology, physics.

[14]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[15]  J. Kim,et al.  Impression of prognosis regarding pathologic stage after preoperative chemoradiotherapy in rectal cancer. , 2015, World journal of gastroenterology.

[16]  Luigia D'Errico,et al.  Colorectal cancer: current imaging methods and future perspectives for the diagnosis, staging and therapeutic response evaluation. , 2013, World journal of gastroenterology.

[17]  D. Dearnaley,et al.  Intensity-modulated radiotherapy in patients with locally advanced rectal cancer reduces volume of bowel treated to high dose levels. , 2006, International journal of radiation oncology, biology, physics.

[18]  Rainer Fietkau,et al.  Preoperative versus postoperative chemoradiotherapy for rectal cancer. , 2004, The New England journal of medicine.

[19]  J. Skibber,et al.  Metformin use and improved response to therapy in rectal cancer , 2013, Cancer medicine.

[20]  Lars Påhlman,et al.  Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Christophe Hennequin,et al.  Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  K. Griffith,et al.  A Phase II Study of Preoperative Capecitabine and Radiation Therapy in Patients With Rectal Cancer , 2007, American journal of clinical oncology.

[23]  J. Coebergh,et al.  Trends in colorectal cancer in the south of the Netherlands 1975–2007: Rectal cancer survival levels with colon cancer survival , 2010, Acta oncologica.

[24]  R. Labianca,et al.  Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Sang‐wook Lee,et al.  Optimal time interval between capecitabine intake and radiotherapy in preoperative chemoradiation for locally advanced rectal cancer. , 2007, International journal of radiation oncology, biology, physics.

[26]  Kieran Sheahan,et al.  Controversies in the pathological assessment of colorectal cancer. , 2014, World journal of gastroenterology.

[27]  L. Boni,et al.  Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  C. Rödel,et al.  Apoptosis as a cellular predictor for histopathologic response to neoadjuvant radiochemotherapy in patients with rectal cancer. , 2002, International journal of radiation oncology, biology, physics.

[29]  N. Petrelli,et al.  The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Transanal endoscopic surgery in rectal cancer. , 2014, World journal of gastroenterology.

[31]  Rafael Martínez-Monge,et al.  Intensity-modulated radiation therapy (IMRT) vs. 3D conformal radiotherapy (3DCRT) in locally advanced rectal cancer (LARC): dosimetric comparison and clinical implications , 2010, Radiation oncology.

[32]  Laurence Collette,et al.  Chemotherapy with preoperative radiotherapy in rectal cancer. , 2006, The New England journal of medicine.

[33]  Jong Hoon Kim,et al.  Ratio of metastatic lymph nodes is more important for rectal cancer patients treated with preoperative chemoradiotherapy. , 2015, World journal of gastroenterology.

[34]  C. Yu,et al.  Current issues in locally advanced colorectal cancer treated by preoperative chemoradiotherapy. , 2014, World journal of gastroenterology.

[35]  S. Wexner,et al.  Pelvic radiation and anorectal function: introducing the concept of sphincter-preserving radiation therapy. , 2002, Journal of the American College of Surgeons.

[36]  A. Melcher,et al.  Preoperative radiotherapy combined with 5 days per week capecitabine chemotherapy in locally advanced rectal cancer , 2007, British Journal of Cancer.

[37]  H. Choi,et al.  Optimal Surgery Time After Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancers , 2008, Annals of surgery.

[38]  D. Goldstein,et al.  Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  E. Roubalová,et al.  Preoperative radiotherapy and concomitant capecitabine treatment induce thymidylate synthase and thymidine phosphorylase mRNAs in rectal carcinoma. , 2007, Neoplasma.

[40]  D. Damin,et al.  Evolving treatment strategies for colorectal cancer: a critical review of current therapeutic options. , 2014, World journal of gastroenterology.

[41]  K. Havenga,et al.  Preoperative Chemoradiotherapy with Capecitabine and Oxaliplatin in Locally Advanced Rectal Cancer. A Phase I–II Multicenter Study of the Dutch Colorectal Cancer Group , 2007, Annals of Surgical Oncology.

[42]  M. Weiser,et al.  Treatment of locally advanced rectal cancer: controversies and questions. , 2012, World journal of gastroenterology.

[43]  H. Christiansen,et al.  Irradiation with protons for the individualized treatment of patients with locally advanced rectal cancer: a planning study with clinical implications. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[44]  T. Briere,et al.  Intensity modulated radiation therapy (IMRT): differences in target volumes and improvement in clinically relevant doses to small bowel in rectal carcinoma , 2011, Radiation oncology.

[45]  B. Uzzan,et al.  Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. , 2009, European journal of cancer.

[46]  P. Kienle,et al.  Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. , 2012, The Lancet. Oncology.

[47]  P. Therasse,et al.  Response evaluation criteria in solid tumors (RECIST): new guidelines. , 2001, Medical and pediatric oncology.

[48]  Wei Wu,et al.  Silencing Fas-associated phosphatase 1 expression enhances efficiency of chemotherapy for colon carcinoma with oxaliplatin. , 2010, World journal of gastroenterology.

[49]  K. Bujko,et al.  Neoadjuvant treatment for unresectable rectal cancer: an interim analysis of a multicentre randomized study. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[50]  J. Meyerhardt,et al.  Adjuvant Treatment of Colorectal Cancer , 2007, CA: a cancer journal for clinicians.

[51]  P. Quirke,et al.  Rates of Circumferential Resection Margin Involvement Vary Between Surgeons and Predict Outcomes in Rectal Cancer Surgery , 2002, Annals of surgery.

[52]  V. Lorvidhaya,et al.  Preoperative capecitabine with pelvic radiotherapy for locally advanced rectal cancer (phase I trial). , 2006, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[53]  R. Costi,et al.  TOPIC HIGHLIGHT , 2014 .

[54]  C. Hennequin,et al.  Preoperative Treatment Combining Capecitabine with Radiation Therapy in Rectal Cancer: A GERCOR Phase II Study , 2008, Oncology.

[55]  N. Petrelli,et al.  Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  J. Jin,et al.  A phase I study of concurrent radiotherapy and capecitabine as adjuvant treatment for operable rectal cancer. , 2006, International journal of radiation oncology, biology, physics.

[57]  Bernard Leduc,et al.  Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  B. Glimelius Multidisciplinary treatment of patients with rectal cancer: Development during the past decades and plans for the future , 2012, Upsala journal of medical sciences.

[59]  L. Påhlman,et al.  Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer – the RAPIDO trial , 2013, BMC Cancer.

[60]  L. Påhlman,et al.  Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer , 2010, The British journal of surgery.

[61]  P. Adeleine,et al.  Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  W. Hohenberger,et al.  Neoadjuvant treatment with weekly high-dose 5-fluorouracil as a 24h-infusion, folinic acid and biweekly oxaliplatin in patients with primary resectable liver metastases of colorectal cancer: long-term results of a phase II trial. , 2008, Medical science monitor : international medical journal of experimental and clinical research.

[63]  Sijuan Huang,et al.  Dosimetric Comparison of Volumetric Modulated Arc Therapy (VMAT), 5F Intensity Modulated Radiotherapy (IMRT) and 3D Conformal Radiotherapy (3DCRT) in Rectal Carcinoma Receiving Neoadjuvant Chemoradiotherapy , 2015 .

[64]  F. Rotondi,et al.  Concomitant boost radiotherapy and multidrug chemotherapy in the neoadjuvant treatment of locally advanced rectal cancer: Results of a phase II study , 2011, Acta oncologica.